Bevacizumab Biosimilars Market Analysis 2025–2029: Growth Forecast and Competitive Insights

Uncover key drivers, emerging technologies, and competitive movements shaping the bevacizumab biosimilars market from 2025–2034 with trusted insights from The Business Research Company

How Much Will The Bevacizumab Biosimilars Market Be Worth By 2029, And What CAGR Will It Achieve?

The bevacizumab biosimilars market size has witnessed substantial growth in recent years. It is projected to expand from $1.53 billion in 2024 to $1.64 billion in 2025, achieving a compound annual growth rate (CAGR) of 7.2%. This historical growth can be attributed to several factors, including patent expiry, cost containment measures in healthcare, the increasing incidence of cancer, heightened market competitiveness, improved patient access and affordability, and the growing acceptance of biosimilars.

The bevacizumab biosimilars market is anticipated to experience substantial expansion in the coming years. This market is projected to reach $2.23 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 7.9%. Several factors are expected to contribute to this growth during the forecast period, including the increasing need for cancer therapies, proficiency in biosimilar development expertise, strains on healthcare system pressures, the evolving biosimilar regulatory landscape, and the concept of biosimilar interchangeability. Additionally, key trends anticipated within this period encompass collaborations and partnerships, progress in regulatory advancements and approvals, innovation in biosimilar development, strategic approaches to market access, and the management of biosimilar lifecycle management.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10848&type=smp

Which Factors Are Driving The Bevacizumab Biosimilars Market Forward?

The escalating occurrence of cancer cases is projected to stimulate the growth of the bevacizumab biosimilar market. Cancer incidence refers to the count of new cancer diagnoses observed in a particular demographic over a specific period. Bevacizumab is a biologic treatment that functions by inhibiting tumor angiogenesis, which can lead to the shrinking and halted growth of tumors, demonstrating comparable efficacy and safety to reference biologics when treating individuals with advanced non-small cell lung cancer or metastatic colorectal cancer. For instance, in October 2024, the UK’s National Health Service (NHS) reported 346,217 new cancer diagnoses in 2022, averaging 948 cases each day. This marks a 5% increase when compared to the 329,664 diagnoses from 2021. Furthermore, cancer diagnoses experienced a 7% rise, growing from 167,917 to 180,877 in 2022. Therefore, the increasing prevalence of cancer cases acts as a key driver for the bevacizumab biosimilars market.

Which Segments Form The Key Structure Of The Bevacizumab Biosimilars Market?

The bevacizumab biosimilars market covered in this report is segmented –

1) By Product: Avastin, Mvasi, Zirabev, Aybintio, Other Products

2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Distribution Channels

3) By Application: Colorectal Cancer, Non-small Cell Lung Cancer, Glioblastoma, Renal Cell Carcinoma, Cervical Cancer, Ovarian Cancer

Subsegments:

1) By Avastin: Original Avastin Product

2) By Mvasi: Mvasi (Amgen Biosimilar)

3) By Zirabev: Zirabev (Pfizer Biosimilar)

4) By Aybintio: Aybintio (Samsung Bioepis Biosimilar)

5) By Other Products: Additional Bevacizumab Biosimilars

What Strategic Shifts And Innovations Are Influencing The Bevacizumab Biosimilars Market?

Product innovation has emerged as a key trend gaining significant traction in the bevacizumab biosimilars market. Major market players are concentrating their efforts on developing new products to strengthen their position. For instance, in May 2022, Viatris, a US-based pharmaceutical company, and Biocon Biologics, a US-based pharmaceutical company, introduced Abevmy (bevacizumab), a biosimilar akin to Roche’s Avastin (bevacizumab). Abevmy has received approval from Health Canada for use across four oncology indications. The product demonstrates efficacy, safety, and quality comparable to the reference biologic, functioning as a synthesized humanized monoclonal antibody (MA) that binds to and neutralizes the biologic action of human vascular endothelial growth factor (VEGF).

Which Firms Are Making The Biggest Impact In The Bevacizumab Biosimilars Market?

Major companies operating in the bevacizumab biosimilars market include Cipla Limited, Reliance lifesciences Pvt. Ltd., Fujifilm Kyowa Kirin Biologics Co. Ltd., Pfizer Inc., F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Mylan Inc., Daiichi Sankyo Company Limited, Beaconpharma Ltd., Innovent Biologics Inc., STADA Arzneimittel AG, Shanghai Henlius Biotech Inc., Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd., Biocon Ltd., Intas Pharmaceuticals Ltd., Amneal Pharmaceuticals LLC, Samsung Bioepis Co. Ltd., Celltrion Inc., Coherus BioSciences Inc., Hetero Drugs Ltd., Apotex Inc., BioXpress Therapeutics SA, mAbxience SA

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/bevacizumab-biosimilars-global-market-report

Which Region Is Expected To Lead The Bevacizumab Biosimilars Market In The Next Few Years?

North America was the largest region in the bevacizumab biosimilars market in 2024. The regions covered in the bevacizumab biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=10848&type=smp

Browse Through More Reports Similar to the Global Bevacizumab Biosimilars Market 2025, By The Business Research Company

Adalimumab Infliximab And Etanercept Biosimilar Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/adalimumab-infliximab-and-etanercept-biosimilar-global-market-report

Filgrastim Biosimilar Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/filgrastim-biosimilar-global-market-report

Oncology Biosimilar Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/oncology-biosimilar-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795